Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer
Author:
Affiliation:
1. Vector Oncology, an affiliate of ConcertAI, 6555 Quince, Suite 400, Memphis, TN 38119, USA
2. Merck & Co., Inc., 351 N. Sumneytown Pike, North Wales, PA 19454, USA
3. West Cancer Center, 7945 Wolf River Boulevard, Germantown, TN 38138, USA
Abstract
Funder
Merck
Publisher
Future Medicine Ltd
Subject
Cancer Research,Oncology,General Medicine
Link
https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-1021
Reference21 articles.
1. Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
2. Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
3. Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials
4. Cancer statistics, 2019
5. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Geographic and sociodemographic access to systemic anticancer therapies for secondary breast cancer: a systematic review;Systematic Reviews;2024-01-18
2. Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer;DNA and Cell Biology;2023-02-01
3. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer;Breast Cancer: Basic and Clinical Research;2023-01
4. The impact of geographical and sociodemographic variation on access to Systemic Anti- Cancer Therapies for Secondary Breast Cancer: A systematic review;2022-10-18
5. Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study (Preprint);2022-10-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3